Alembic intros Docetaxel injection
Docetaxel injection is a microtubule inhibitor indicated for treating patients with several types of cancer after failure of prior chemotherapy.
Alembic is introducing Docetaxel injection, 20 mg/2 ml (10 mg/ml), 80 mg/8 ml (10 mg/ml) and 160 mg/16 ml (10 mg/ml), which is the generic of Hospira’s Docetaxel injection.
Docetaxel injection is a microtubule inhibitor. It is indicated for treating patients with locally advanced or metastatic breast cancer, non-small cell lung cancer, castration-resistant prostate cancer, gastric adenocarcinoma and squamous cell carcinoma of the head and neck after the failure of prior chemotherapy.
[Read more: Alembic rolls out generic Hygroton]
Alembic will offer Docetaxel injection in 20 mg/2 ml single-dose vials, and 80 mg/8 ml and 160 mg/16 ml multiple-dose vials.